22.83

1.33% 0.30

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Financials Discussions Forecast

Arcus Biosciences Inc stock is traded at $22.83, with a volume of 590.25K. It is up +1.33% in the last 24 hours and down -6.13% over the past month. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Previous Close:

$22.53

Open:

$22.53

24h Volume:

590.25K

Relative Volume:

0.46

Market Cap:

$2.91B

Revenue:

$236.00M

Net Income/Loss:

$-369.00M

P/E Ratio:

-7.1729

EPS:

-3.1828

Net Cash Flow:

$-489.00M

1W Performance:

-4.20%

1M Performance:

-6.13%

6M Performance:

-3.67%

1Y Performance:

+35.09%

1-Day Range:

$22.53

$23.28

1-Week Range:

$22.36

$24.73

52-Week Range:

$15.38

$31.73

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

601

Twitter

@arcusbio

Next Earnings Date

2026-10-27

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	22.83	2.91B	236.00M	-369.00M	-489.00M	-3.1828
VRTX Vertex Pharmaceuticals Inc	509.86	129.23B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.75	94.92B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	800.00	82.36B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.32	53.35B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.60	42.04B	5.76B	514.49M	1.10B	4.4813

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-16-26	Initiated	TD Cowen	Buy
May-18-26	Resumed	Truist	Buy
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-13-26	Upgrade	Goldman	Neutral → Buy
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Oct 10, 2026

Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage? - Yahoo Finance

Oct 06, 2026

Arcus Biosciences stock falls 2.79 percent before ARC-20 data - ad-hoc-news.de

Oct 06, 2026

Oct 05, 2026

Arcus Biosciences stock gains 1.49 percent ahead of data event - ad-hoc-news.de

Oct 05, 2026

Wall Street Zen upgrades Arcus Biosciences stock to Hold - ad-hoc-news.de

Oct 05, 2026

Oct 04, 2026

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data - Yahoo Finance

Oct 04, 2026

Oct 03, 2026

Arcus Biosciences (RCUS) Pulls Back 3.13% to $24.44, Testing Key SupportBreak of Structure - siam.in

Oct 03, 2026